AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2023
Jan 4, 2023
31100_dirs_2023-01-04_83e41db3-e624-4ab2-a525-09ce67c3d27c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-12-30
Reporting Person: Dhaliwal Harpreet S. (SVP Cml Mfg & Supply Chain)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-30 | Stock Option (right to buy) | $47.95 | A | 15000 | Acquired | 2032-12-30 | Common Stock (15000) | Direct |
Footnotes
F1: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 24